Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NexImmune raises $23mm through Series A round

Executive Summary

NexImmune Inc. (immunotherapies for cancer) raised $23mm through its Series A round. New investor ArrowMark Partners and existing investor Barer & Son were the co-leads, and were joined by Piedmont Capital. (A syndicate of investors led by Barer & Son acquired NexImmune in early 2017.) NexImmune is developing drugs based on its Artificial Immune Modulation (AIM) nanotechnology platform, and will use the Series A proceeds to advance its first adoptive cellular therapy (ACT) into Phase I/II trials for blood cancers. The company claims that its technology could eventually be applied to therapies for infectious diseases, but for now is focusing on solid and blood tumors.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies